Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Blood transcriptome biomarkers in IBD

ABSTRACT: Redefining the practical utility of blood transcriptome biomarkers in inflammatory bowel diseases

PROVIDER: PRJEB28822 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR2814730.fastq.gz	Fastqsanger.gz
	ERR2814740.fastq.gz	Fastqsanger.gz
	ERR2814760.fastq.gz	Fastqsanger.gz
	ERR2814770.fastq.gz	Fastqsanger.gz
	ERR2817080.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 336

Similar Datasets

IBD-T2DM

Project description:Gut Microbiota Analyses of Inflammatory Bowel Diseases from a representative Saudi Population

| PRJEB57347 | ENA

Whole blood expression profiling of patients with inflammatory bowel diseases in IBD-Character cohort

Project description:The IBD-Character cohort (Edinburgh, Oslo, Örebro, Linköping, Zaragoza, Maastricht) included patients with inflammatory bowel diseases (IBD: Crohn's disease, ulcerative colitis) recruited at diagnosis and non-IBD controls. Paired-end RNA sequencing was used for whole blood expression profiling. Raw and normalized counts tables are provided.

2022-03-01 | E-MTAB-11349 | biostudies-arrayexpress

IBD CosMx NanoString data from colonic mucosa

Project description:Inflammatory bowel diseases (IBDs) including ulcerative colitis (UC) and Crohn’s disease (CD) are chronic inflammatory diseases with increasing worldwide prevalence that show a perplexing heterogeneity in manifestations and response to treatment. We applied spatial transcriptomics at single-cell resolution (CosMx Spatial Molecular Imaging) to human inflamed and uninflamed intestine.

2023-06-13 | GSE234713 | GEO

IBD single cell data from colonic mucosa

Project description:Inflammatory bowel diseases (IBDs) including ulcerative colitis (UC) and Crohn’s disease (CD) are chronic inflammatory diseases with increasing worldwide prevalence that show a perplexing heterogeneity in manifestations and response to treatment. We applied single cell RNA sequencing (scRNAseq) a to colonic tissue from a combined healthy, UC and CD cohort.

2023-06-07 | GSE214695 | GEO

Low mass blood peptides discriminative of IBD severity

Project description:The enriched low mass proteome is unexplored as a source of differentiators for diagnosing and monitoring Inflammatory Bowel Disease (IBD) activity, less invasively than colonoscopy and histopathology. Differences in the enriched low mass plasma proteome (<25kDa) were assessed by label-free quantitative mass-spectrometry. A panel of marker candidates were progressed to validation phase and ‘Tier-2’ FDA-level validated quantitative assay. Proteins important in maintaining gut barrier function and homeostasis at the epithelial interface have been quantitated by Multiple Reaction Monitoring (MRM) in plasma and serum including both inflammatory rheumatoid arthritis controls (RA) and non-inflammatory healthy controls (C), ulcerative colitis (UC) and crohn’s disease (CD) patients. Detection by immunoblot confirmed presence at the protein level in serum. Correlation analysis and receiver operator characteristics were used to report the sensitivity and specificity. Five peptides discriminating IBD activity and severity had very little-to-no correlation to Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), white cell or platelet counts. Three of these peptides were found to be binding partners to SPP24 protein alongside other known matrix proteins. These Proteins have the potentially improve effective diagnosis and evaluate IBD activity, reducing the need for more invasive techniques.

2015-11-06 | PXD002821 | Pride

IBD

Project description:WTCCC1 project Inflammatory Bowel Disease (IBD) samples

| EGAD00000000005 | EGA

Data-Independent Acquisition Analysis to Identify Serum Biomarkers and Neoantigens for Differentiating Colorectal Cancer from Inflammatory Bowel Disease

Project description:Early detection of colorectal cancer (CRC) and distinguishing inflammatory bowel diseases from cancerous conditions significantly improve survival rates. While colonoscopy is the gold standard for CRC detection, it is invasive and associated with potential complications. Therefore, there is a need for blood biomarkers that possess high sensitivity and specificity which can be used for pre-diagnosis. In this study, we screened for serum biomarkers specifically altered in colonoscopy-positive (CP) patients (cancer group) when compared to colonoscopy-negative (CN) patients (suffering from other bowel-related illnesses with symptoms similar to CRC), and healthy control (HC) individuals (n=20 each). Using Data-Independent Acquisition-Mass spectrometry (DIA-MS) analysis, we identified potential protein markers and neoantigens uniquely altered in the CP group compared to the CN group.

2025-06-10 | PXD055218 | Pride

Discovery and Validation of Serum Biomarkers and Neoantigens for Differentiating Colorectal Cancer from Inflammatory Bowel Diseases

2025-06-23 | PXD065161 | Pride

Predicting response to vedolizumab therapy using mucosal transcriptomics in IBD patients

Project description:In this study we wanted to identify baseline predictors of successful vedolizumab therapy in patients with inflammatory bowel disease.

2019-08-23 | E-MTAB-7845 | biostudies-arrayexpress

snuh-ibd-bacterial-amplicon

Project description:Seoul National University Hospital Inflammatory Bowel Disease Metagenomic Study

| PRJEB101301 | ENA